Nav: Home

Study finds Velcade major improvement over standard therapy for relapsed multiple myeloma patients

June 05, 2004

NEW ORLEANS--Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.

The findings, which will be presented at the annual meeting of the American Society of Clinical Oncology (Sunday, June 6, 2 p.m. Room 283) were sufficiently striking that the trial was stopped early so that patients who had been randomly assigned to receive dexamethasone could switch to bortezomib.

The study, which involved 669 patients in 92 treatment centers around the world, was the first head-to-head comparison of bortezomib and dexamethasone in a Phase III trial of patients who had relapsed after treatment for multiple myeloma. (Phase III trials test new treatments against standard ones to determine which is safer and more effective.)

"This trial represents the largest, most broad-based assessment to date of bortezomib and dexamethasone in this group of patients," says the study's lead author, Paul Richardson, MD, of Dana-Farber. "The finding that bortezomib significantly lengthened the time to disease progression and improved survival when compared with dexamethasone, with a similar level of safety, is important confirmatory evidence of bortezomib's effectiveness for patients with relapsed multiple myeloma."

Multiple myeloma is a currently incurable cancer of the bone marrow that causes a plunge in the production of vital red and white blood cells. Although relatively rare, it is the second most common type of blood cancer and accounts for 11,000 deaths annually in the United States. It is the fourth fastest-growing cancer in terms of mortality and is among the top 10 causes of death among African Americans.

In the new study, researchers randomly assigned 669 relapsed myeloma patients to receive a six-month course of either bortezomib or dexamethasone, then tracked them to determine when - and if - the disease began to progress. For patients receiving dexamethasone, the average time to progression was 3.6 months; for those receiving bortezomib, the average time was 5.7 months. Overall survival was also higher among the bortezomib patients, 13 of whom died during the trial period, compared to 24 of those receiving dexamethasone. A somewhat lower rate of serious infections was found in the bortezomib patients.

"For the patients receiving bortezomib, the average 5.7-month period before progression of the disease represents a 58 percent increase over that achieved by the dexamethasone-treated group," Richardson commented. "This points to a significant improvement in efficacy, which prompted the trial's Data Monitoring Committee to halt the trial early so all patients participating in the study could receive bortezomib."

Manufactured by Millennium Pharmaceuticals of Cambridge, Mass., Velcade is the first of a class of substances known as proteasome inhibitors to reach the clinical trial stage. Preclinical studies by researchers at Dana-Farber demonstrated that the drug - which acts on intracellular structures called proteasomes, which control the degradation of key proteins controlling myeloma cells - prevented tumor cells from proliferating, and was active even against those that were resistant to other known therapies. Later experiments found that the drug killed myeloma cells in mice without causing serious harm to normal tissue.

The latest study follows a series of Phase I studies and a pivotal, large, multicenter Phase II trial led by Richardson and the team at Dana-Farber. That trial, which involved 202 patients with relapsed and treatment-resistant myeloma, showed bortezomib to be highly active and to have manageable side effects, leading to its rapid approval by the Food and Drug Administration last year. Ongoing studies will now focus on the rate and duration of response to bortezomib, safety, and survival earlier in the disease process, and in combination with other drugs.
Collaborating with Richardson and senior author Kenneth Anderson, MD, were researchers at University Hospital Rotterdam, the Netherlands; New York Presbyterian Hospital, New York City; Alta Bates Cancer Center, Berkeley Calif.; University of Pennsylvania Cancer Center; Hospital Claude Huriez, Lille, France; H. Lee Moffitt Cancer Center, Tampa, Fla.; Hotel Dieu Hospital, Nantes, France; and Hospital Universitario de Salamanca, Spain.

Dana-Farber Cancer Institute ( is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center, designated a comprehensive cancer center by the National Cancer Institute.

Dana-Farber Cancer Institute

Related Multiple Myeloma Articles:

CAR T-Cell therapy sends multiple myeloma into lasting remission
In an early clinical trial, 33 out of 35 (94 percent) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy -- chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA.
Using a rabbit virus to treat multiple myeloma
Treating multiple myeloma (MM) with myxoma virus (MYXV) eliminated a majority of malignant cells in preclinical studies, report investigators at the Medical University of South Carolina (MUSC) and elsewhere in an article published online on Dec.
Inhibition of EZH2 might be new therapy of multiple myeloma
In a study published in the scientific journal Oncotarget, researchers from Uppsala University show how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease.
Additions to standard multiple myeloma therapy do not appear to yield additional benefit
Trial results being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone.
Early treatment may prevent progression to multiple myeloma
Early intervention with an immunotherapy-based drug combination may prevent progression of high-risk 'smoldering' multiple myeloma to the full-blown disease, according to researchers from Dana-Farber Cancer Institute.
Advances in multiple myeloma, lymphoma and other hematologic malignancies presented at ASH
Researchers from UH Seidman Cancer Center and Case Western Reserve University School of Medicine presented new findings in multiple myeloma, lymphoma and other hematologic disorders at Annual Meeting of American Society of Hematology.
Weight loss may help prevent multiple myeloma
Carrying extra weight increases a person's risk that a benign blood disorder will develop into multiple myeloma, a blood cancer.
Researchers take step toward understanding how multiple myeloma takes hold
Scientists are moving closer to understanding how multiple myeloma takes hold in bone marrow by identifying what they believe are the mechanisms used by cancer cells to take over.
Elotuzumab in multiple myeloma: Added benefit not proven
The only study presented was unsuitable for the benefit assessment.
As body mass index increases, so does spread of multiple myeloma
In a new study, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma.

Related Multiple Myeloma Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...